Vivasure Medical, Galway, Ireland-based company pioneering novel fully absorbable technology for percutaneous vessel closure, closed the first tranche of €22m as part of its Series D financing round that could reach up to €52m in total.
LedThe financing is provided by a multinational strategic corporation and includes the option to purchase the company at certain milestones. Other participants inThis round also includes a second strategic corporate investor and existing investors. Fountain Healthcare Partners, OrchestraBioMed, LSP Health Economics FundManaged by the EQT Life Sciences team, Panakès Partners and Evonik Venture Capital.
The company intends to use the funds to advance the U.S. and European clinical development and regulatory approval its portfolio of fully absorbable, patch-based large-bore percutaneous vessel closure devices for transcatheter endovascularAnd cardiovascular procedures, including PerQseal® and PerQseal+ for arterial closure and PerQseal BlueFor venous closure
LedBy Andrew GlassChief Executive Officer, VivasureA medical device company that develops advanced polymer implants and delivery system, primarily focusing on minimally invasive vessel closing. inInterventional radiology, cardiology, and vascular surgeon. ItsPerQseal technology is a bioabsorbable intravascular piece that seals the vessel. It does this without leaving behind any remains of collagen, metal implants, or sutures. inOther closure technologies
ThePhysicians now have the option to use PerQseal, a sutureless and fully absorbable synthetic device for large-bore vessel punctures. in EuropeUse inTranscatheter endovascular procedures include transcatheter aortic replacement (TAVR), transcatheter thoracic aneurysm repairs (TEVAR), and endovascular abdominal resection (EVAR). TheDevice has an enhanced bioabsorbable pad that can address more complex patient anatomy. It is currently being clinically evaluated. in EuropeAmerican and U.S. ItPerQseal is also being developed BlueDesigned for sutureless, fully absorbable large-bore venous vessel closing following percutaneous cardiovascular procedures such as transcatheter tricuspid or transcatheter valve repair or replacement, (TMVR), and leadless pacemaker implant. CurrentlyFollowing large-bore venous procedures, there is no sutureless option for vessel closure.
TheCompany has a fully integrated R&D departmentamp;DManufacturing facility ISO 13485-certified